NCT04471337View on ClinicalTrials.gov

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

February 15, 2021

Study Completion Date

May 6, 2021

Conditions
Endometriosis Related PainOveractive BladderDiabetic Neuropathic PainRefractory or Unexplained Chronic Cough
Interventions
DRUG

BAY1817080

BAY1817080 will be administered orally as tablet.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, LLC, Miami

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY